Last reviewed · How we verify
Aspirin + Acid folic — Competitive Intelligence Brief
phase 3
Antiplatelet agent + vitamin supplement
COX-1 (aspirin); folate metabolism pathway (folic acid)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Aspirin + Acid folic (Aspirin + Acid folic) — Assistance Publique - Hôpitaux de Paris. Aspirin inhibits platelet aggregation via COX inhibition while folic acid supports cellular methylation and DNA synthesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aspirin + Acid folic TARGET | Aspirin + Acid folic | Assistance Publique - Hôpitaux de Paris | phase 3 | Antiplatelet agent + vitamin supplement | COX-1 (aspirin); folate metabolism pathway (folic acid) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antiplatelet agent + vitamin supplement class)
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aspirin + Acid folic CI watch — RSS
- Aspirin + Acid folic CI watch — Atom
- Aspirin + Acid folic CI watch — JSON
- Aspirin + Acid folic alone — RSS
- Whole Antiplatelet agent + vitamin supplement class — RSS
Cite this brief
Drug Landscape (2026). Aspirin + Acid folic — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-acid-folic. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab